0:000:00
<p>More trials at ESC, including PARACHUTE HF, DAPA ACT HF-TIMI 68, AMALFI, and a super-interesting modeling study of when to start oral anticoagulants in AF, are the topics John Mandrola, MD, discusses in this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I PARACHUTE HF</strong></p> <p><strong>First Evidence of Treatment Benefit in Chagas Heart Failure</strong></p> <p> <strong>https://www.medscape.com/viewarticle/first-evidence-treatment-benefit-chagas-heart-failure-2025a1000oem</strong></p> <ul> <li><strong>PARACHUTE-HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021</strong></li> </ul> <p><strong>II SGLT2i Early Initiation — DAPA ACT HF-TIMI 68 Trial</strong></p> <p><strong>Trial Data Support In-Hospital Initiation of SGLT2 Inhibitors for Heart Failure https://www.medscape.com/viewarticle/trial-data-support-hospital-initiatio...